rosiglitazone has been researched along with Kidney, Polycystic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, L; Liu, C; Mei, C; Yuan, L; Zhang, Y | 1 |
| Dai, B; Fu, L; Hua, Z; Liu, Y; Mei, C; Shen, X; Xiong, X; Zhang, Y | 1 |
2 other study(ies) available for rosiglitazone and Kidney, Polycystic
| Article | Year |
|---|---|
Rosiglitazone inhibits insulin-like growth factor‑1-induced polycystic kidney disease cell growth and p70S6 kinase activation.
Topics: Animals; Cell Proliferation; Cells, Cultured; Epithelial Cells; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor I; Kidney Tubules; Mice; Phosphorylation; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant; PPAR gamma; Ribosomal Protein S6 Kinases, 70-kDa; RNA Interference; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones | 2013 |
Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats.
Topics: Animals; Chemokine CCL2; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Drug Evaluation, Preclinical; Hypoglycemic Agents; Male; Polycystic Kidney Diseases; PPAR gamma; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Survival Analysis; Thiazolidinediones; Transforming Growth Factor beta1 | 2010 |